cabergoline has been researched along with Albright Syndrome in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (75.00) | 29.6817 |
2010's | 1 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Asha, HS; Cherian, KE; Paul, TV; Rajan, R | 1 |
Albuquerque, LA; Almeida, JP; Ferraz, CL; Ferraz, TM; Gondim, J; Mota, I | 1 |
Akintoye, SO; Bianco, P; Booher, S; Chebli, C; Cherman, N; Collins, MT; Feuillan, P; Kushner, H; Leroith, D; Robey, PG; Wientroub, S | 1 |
Fujieda, K; Ishi, N; Ishizu, K; Jo, W; Tajima, T; Tsubaki, J | 1 |
4 other study(ies) available for cabergoline and Albright Syndrome
Article | Year |
---|---|
McCune Albright syndrome: an endocrine medley.
Topics: Adenoma; Bone Density Conservation Agents; Cabergoline; Diagnosis, Differential; Dopamine Agonists; Female; Fibrous Dysplasia, Polyostotic; Humans; Hyperthyroidism; Leg; Musculoskeletal Pain; Pituitary Neoplasms; Rare Diseases; Young Adult; Zoledronic Acid | 2019 |
McCune-Albright syndrome and acromegaly: hormonal control with use of cabergoline and long-acting somatostatin--case report.
Topics: Acromegaly; Adenoma; Adult; Antineoplastic Agents, Hormonal; Cabergoline; Ergolines; Facial Bones; Female; Fibrous Dysplasia, Polyostotic; Human Growth Hormone; Humans; Insulin-Like Growth Factor I; Octreotide; Pituitary Neoplasms; Skull | 2009 |
Characterization of gsp-mediated growth hormone excess in the context of McCune-Albright syndrome.
Topics: Adenoma; Antineoplastic Agents; Body Height; Cabergoline; DNA Mutational Analysis; Ergolines; Fibrous Dysplasia, Polyostotic; GTP-Binding Protein alpha Subunits, Gs; Human Growth Hormone; Insulin-Like Growth Factor I; Magnetic Resonance Imaging; Octreotide; Pituitary Neoplasms | 2002 |
Case study of a 15-year-old boy with McCune-Albright syndrome combined with pituitary gigantism: effect of octreotide-long acting release (LAR) and cabergoline therapy.
Topics: Adolescent; Antineoplastic Agents; Cabergoline; Delayed-Action Preparations; Ergolines; Fibrous Dysplasia, Polyostotic; Gigantism; Humans; Male; Octreotide; Radiography | 2008 |